You are here
Ovid Therapeutics Announces Proposed Concurrent Public Offerings of Common Stock and Preferred Stock
NEW YORK, Feb. 19, 2019 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that it intends to offer and sell shares of its common stock and Series A convertible preferred stock (“Series A stock”) in two concurrent but separate underwritten public offerings. Neither of the proposed common stock offering or the Series A stock offering (together, the “Offerings”) are contingent upon the consummation of the other. The Offerings are subject to market and other conditions, and there can be no assurance as to whether or when the Offerings may be completed, or the actual size or terms of the Offerings.
Tuesday, February 19, 2019 - 16:01